Melanoma Parallel Session

Thursday, March 21, 2024

1:55pm – 3:25pm ET

Location:C102

Moderator(s)

Jeffrey Gershenwald, MD (he/him/his)

Professor
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Houston, Texas, United States

Disclosure(s): Merck: Advisor (Ongoing), Consultant (Ongoing), Contracted Research (Ongoing)
Elizabeth Lilley, MD, MPH (she/her/hers)

Associate Surgeon
Brigham and Women's Hospital
Boston, Massachusetts, United States

Disclosure(s): No financial relationships to disclose

Disclosure(s):

Jeffrey E. Gershenwald, MD: Merck: Advisor (Ongoing), Consultant (Ongoing), Contracted Research (Ongoing)

Elizabeth J. Lilley, MD, MPH: No financial relationships to disclose

Presentations:

1:57pm – 2:07pm ET

60: Management and outcomes of patients with recurrence of cutaneous melanoma during or after completion of adjuvant immunotherapy: a multicenter study
Abstract Presenter: Sophia McKinley, MD EdM (she/her/hers) – Massachusetts General Hospital
Submitter: Sophia McKinley, MD EdM (she/her/hers) – Massachusetts General Hospital
Author: Sophia McKinley, MD EdM (she/her/hers) – Massachusetts General Hospital
Author: Hannah L. Kalvin, MSPH – Memorial Sloan Kettering Cancer Center
Author: Mackenzie L. Shindorf, MD – University of Louisville
Author: Kristen E. Rhodin, MD, MHS – Duke University Medical Center
Author: Murtuza Saifuddin, MD – Sunnybrook Health Sciences Centre
Author: Christine Tran, BA – UVA
Author: Gabrielle Schwartzman, MD – UVA
Author: Cimarron E. Sharon, MD – University of Pennsylvania
Author: Aleigha Lawless, BA – Massachusetts General Hospital
Author: Giorgos Karakousis, MD – Hospital of the University of Pennsylvania
Author: Elizabeth Gaughan, MD – UVA
Author: Craig Slingluff, MD – UVA
Author: Frances C. Wright, MD MEd – Sunnybrook Health Sciences Centre
Author: Genevieve M. Boland, MD, PhD – Massachusetts General Hospital
Author: Katherine Panageas, DrPH – MSKCC
Author: Georgia M. Beasley, MD MHS (she/her/hers) – Duke University Medical Center
Author: Michael E. Egger, MD, MPH – University of Louisville
Author: Edmund Bartlett, MD – MSKCC
2:07pm – 2:17pm ET

61: Surgical considerations for tumor-infiltrating lymphocyte (TIL) therapy in melanoma: results from a randomized phase 3 trial.
Author: Liselotte Tas, MD (she/her/hers) – Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands
Submitter: Liselotte Tas, MD (she/her/hers) – Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands
Author: Marie B. Weitemeyer, MD – Department of Plastic Surgery, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
Author: Maartje W. Rohaan, MD – Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, Amsterdam, The Netherlands
Author: Troels H. Borch, MD, PhD – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte,Herlev, Denmark
Author: Alexander C.J van Akkooi, MD, PhD (he/him/his) – Melanoma Institute Australia / University of Sydney, Faculty of Medicine and Health / Royal Prince Alfred Hospital, Department of Melanoma and Surgical Oncology
Author: Michel W.J.M. Wouters, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Koen J. Hartemink, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Yvonne Schrage, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Anke Kuijpers, MD, PhD – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Author: Maaike Van Zon, BSc – Netherlands Cancer Institute, Biotherapeutics Unit, Amsterdam, The Netherlands
Author: Inge jedema, PhD – Division of Molecular Oncology and Immunology, Netherlands Cancer Institute
Author: Cynthia Nijenhuis, PhD – Netherlands Cancer Institute, Biotherapeutics Unit, Amsterdam, The Netherlands
Author: Bastiaan Nuijen, PhD – Netherlands Cancer Institute, Division of Pharmacy and Pharmacology, Amsterdam, The Netherlands
Author: Sebastian Klobuch, MD – Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands
Author: Ferry Lalezari, MD – Netherlands Cancer Institute, Division of Radiology, Amsterdam, The Netherlands
Author: Marco Donia, MD, PhD – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
Author: Inge Marie Svane, MD, PhD – National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
Author: John B.A.G. Haanen, MD, PhD – Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands
Author: Lisbet R. Holmich, MD, DMSc – Department of Plastic Surgery, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark
Author: Winan J. van Houdt, MD, PhD, MS – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
Abstract Presenter: Winan J. van Houdt, MD, PhD, MS – Netherlands Cancer Institute, Division of Surgical Oncology, Amsterdam, The Netherlands
2:17pm – 2:27pm ET

62: Prospective validation of the integrated 31-gene expression profile test for cutaneous melanoma to select patients who may consider foregoing sentinel lymph node biopsy
Abstract Presenter: J. Michael Guenther, MD – St Elizabeth Physicians
Author: Andrew Ward, PhD – Division of Surgical Oncology, University of Tennessee Medical Center
Author: Brian Martin, PhD – Castle Biosciences, Inc.
Author: Rohit Sharma, MD, FACS – Marshfield Medical Center
Author: Maki Yamamoto, MD – School of Medicine, University of California-Irvine
2:27pm – 2:37pm ET

63: An Externally Validated Online Tool To Calculate Personalized Probabilities Of Recurrence-Free And Overall-Survival In Stage II Melanoma Patients.
Abstract Presenter: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Submitter: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Author: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Author: Isabel Li, n/a – University of Sydney
Author: Mary-Ann El Sharouni, MD PhD – University of Utrecht
Author: Julie Simon, MD – MD Anderson Cancer Center
Author: Aikaterini Dedeilia, MD (she/her/hers) – Massachusetts General Hospital
Author: Robyn Saw, MBBS, FRACS, MS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Andrew Spillane, MBBS, MD, FRACS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Kerwin Shannon, MBBS, FRACS – Melanoma Institute Australia
Author: Jonathan R. Stretch, DPhil FRACS – Melanoma Institute Australia
Author: Ryan J. Sullivan, MD – Massachusetts General Hospital
Author: Genevieve M. Boland, MD, PhD – Massachusetts General Hospital
Author: Jeffrey E. Gershenwald, MD (he/him/his) – Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
Author: Paul van Diest, MD – University of Utrecht
Author: Richard Scolyer, BMedSci MBBS MD FRCPA FRCPath(UK) FAHMS – Melanoma Institute Australia
Author: Georgina V. Long, MBBS PhD – Melanoma Institute Australia
Author: John Thompson, MBBS, MD, DSc, FRACS, FACS (Hon), FAHMS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Serigne N. Lo, PhD – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
2:37pm – 2:47pm ET

64: Hepatic and Overall Progression-Free Survival after Percutaneous Hepatic Perfusion as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma
Abstract Presenter: Helana Ghali, BS – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Submitter: Helana Ghali, BS – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Author: Helana Ghali, BS – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Author: Michelle M. Dugan, MD – Cutaneous Oncology Department, Moffitt Cancer Center, Tampa, FL
Author: Shaliz Aflatooni, BS (she/her/hers) – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Author: Aleena Boby, B.A. (she/her/hers) – University of South Florida Morsani College of Medicine, University of South Florida, Tampa, FL
Author: Danielle K. DePalo, MD (she/her/hers) – Department of General Surgery, University of Massachusetts Chan Medical School, Boston, MA
Author: Jose Laborde, PhD – Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa FL
Author: Jonathan S. Zager, MD – H. Lee Moffitt Cancer Center and Research Institute
2:47pm – 2:57pm ET

65: Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma
Abstract Presenter: Amanda R. Kirane, MD, PhD (she/her/hers) – Stanford University
Submitter: David Lee, B.A. (he/him/his) – Loma Linda University School of Medicine
Author: M. Usman Ahmad, MD (he/him/his) – Stanford University
Author: Saurabh Sharma, Ph.D. – Stanford University
Author: Mamatha Serasanambati, Ph.D. – Stanford University
Author: Michael C. Lowe, MD, MA – Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University
Author: Christopher Applebee, Ph.D. – University of Bath
Author: Elena Safrygina, Ph.D. – University of Bath
Author: Susan Swetter, M.D. – Stanford University
Author: Sunil Reddy, M.D. – Stanford University
Author: Alison Warner, M.D., Ph.D. – Stanford University
Author: Pauline Funchain, M.D. – Stanford University
Author: Jennifer Wang, M.D. – Stanford University
Author: Ronald Levy, M.D. – Stanford University
Author: Banafshe Larijani, n/a – University of Bath
Author: Emanual Maverakis, M.D. – UC Davis
2:57pm – 3:07pm ET

66: Improved Survival with Sentinel Node Biopsy - An Emulated Randomized Controlled Trial
Abstract Presenter: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Submitter: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Author: Alexander H R Varey, MBChB MRCS(Eng) FRACS FRCS(Plast) PhD (he/him/his) – Melanoma Institute Australia, University of Sydney, Westmead Hospital
Author: Raphael P. Feser, n/a – Melanoma Institute Australia
Author: Nurudeen A. Adegoke, n/a – Melanoma Institute Australia
Author: Richard Scolyer, BMedSci MBBS MD FRCPA FRCPath(UK) FAHMS – Melanoma Institute Australia
Author: John Thompson, MBBS, MD, DSc, FRACS, FACS (Hon), FAHMS – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
Author: Serigne N. Lo, PhD – Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
3:07pm – 3:17pm ET

67: The Role of Neoadjuvant Immunotherapy in the Management of Merkel Cell Carcinoma with Clinically Detected Regional Lymph Node Metastasis
Abstract Presenter: Jenny H. Chang, MD (she/her/hers) – Cleveland Clinic
Submitter: Jenny H. Chang, MD (she/her/hers) – Cleveland Clinic
Author: Jenny H. Chang, MD (she/her/hers) – Cleveland Clinic
Author: Daphne Remulla, MD – Cleveland Clinic
Author: Chase J. Wehrle, MD – Cleveland Clinic
Author: Kimberly P. Woo, MD – Cleveland Clinic
Author: Daniel Joyce, MBBCh – Cleveland Clinic
Author: Samer A. naffouje, MD – Cleveland Clinic Foundation